Tower Research Capital LLC (Trc) Arcus Biosciences, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,727 shares of RCUS stock, worth $98,886. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,727

Previous 18,515 63.67%

Holding current value

$98,886

Previous $281,000 63.7%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $161,377 - $212,301	-11,788 Reduced 63.67%	6,727 $102,000
Q2 2024 Aug 13, 2024	BUY	$14.59 - $18.48 $261,569 - $331,309	17,928 Added 3054.17%	18,515 $281,000
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $28,577 - $38,886	-1,927 Reduced 76.65%	587 $11,000
Q4 2023 Feb 13, 2024	SELL	$13.43 - $19.63 $30,486 - $44,560	-2,270 Reduced 47.45%	2,514 $48,000
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $45,706 - $61,062	-2,594 Reduced 35.16%	4,784 $85,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $59,225 - $76,884	3,490 Added 89.76%	7,378 $149,000
Q1 2023 May 09, 2023	SELL	$15.96 - $23.15 $51,806 - $75,144	-3,246 Reduced 45.5%	3,888 $71,000
Q4 2022 Feb 10, 2023	BUY	$19.7 - $35.71 $53,387 - $96,774	2,710 Added 61.26%	7,134 $147,000
Q3 2022 Nov 10, 2022	SELL	$23.23 - $30.07 $198,616 - $257,098	-8,550 Reduced 65.9%	4,424 $115,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $179,674 - $393,448	10,428 Added 409.58%	12,974 $329,000
Q1 2022 May 12, 2022	SELL	$28.92 - $41.83 $59,286 - $85,751	-2,050 Reduced 44.6%	2,546 $81,000
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $92,727 - $143,228	-2,955 Reduced 39.13%	4,596 $186,000
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $78,689 - $110,100	2,922 Added 63.12%	7,551 $263,000
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $1,046 - $1,645	-46 Reduced 0.98%	4,629 $128,000
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $70,605 - $111,711	2,699 Added 136.59%	4,675 $131,000
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $84,864 - $161,541	-4,992 Reduced 71.64%	1,976 $51,000
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $233,978 - $347,690	-13,651 Reduced 66.21%	6,968 $119,000
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $288,047 - $753,830	20,619 New	20,619 $510,000
Q4 2019 Feb 07, 2020	SELL	$7.33 - $10.79 $7,711 - $11,351	-1,052 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$6.44 - $10.18 $6,774 - $10,709	1,052 New	1,052 $10,000
Q2 2019 Aug 13, 2019	SELL	$7.29 - $13.38 $35,502 - $65,160	-4,870 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$8.95 - $12.49 $43,586 - $60,826	4,870 New	4,870 $61,000
Q4 2018 Feb 14, 2019	SELL	$9.74 - $14.5 $545 - $812	-56 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$10.88 - $14.95 $23,500 - $32,292	-2,160 Reduced 97.47%	56 $1,000
Q2 2018 Aug 15, 2018	BUY	$12.24 - $17.05 $27,123 - $37,782	2,216 New	2,216 $27,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Arcus Biosciences, Inc. Transaction History